Semaglutide vs. Tirzepatide for Weight Loss: What’s the Difference?
Learn how semaglutide and tirzepatide compare for weight loss, including how they work, average results, dosing, side effects, costs, and considerations when switching treatments.
WEIGHT MANAGEMENT
Sarina Helton, FNP-C, MSN, CAE-OM
9/10/20269 min read
Semaglutide vs. Tirzepatide for Weight Loss: What’s the Difference?
How the Medications Work, How Much Weight People Lose, and How to Decide Which May Be Appropriate
Semaglutide and tirzepatide are two of the most effective medications currently available for chronic weight management. Both are taken once weekly by injection, reduce hunger, increase fullness, and can produce clinically meaningful weight loss.
However, they are not the same medication—and tirzepatide is not simply a “stronger dose” of semaglutide.
Tirzepatide produces greater average weight loss in clinical trials, including a direct head-to-head comparison. That does not mean it is automatically the best medication for every patient. Medical history, treatment response, side effects, pregnancy potential, insurance coverage, availability, and cost all matter.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist. It acts like glucagon-like peptide-1, a naturally occurring hormone involved in appetite regulation and glucose control.
Semaglutide can:
Increase fullness after eating
Reduce hunger
Decrease food intake
Slow gastric emptying, particularly earlier in treatment
Stimulate insulin release when glucose is elevated
Reduce inappropriate glucagon secretion
Semaglutide is the active ingredient in several products, but their indications and doses differ:
Wegovy: FDA-approved for chronic weight management in eligible patients and for certain additional indications
Ozempic: FDA-approved for type 2 diabetes and certain risk-reduction indications—not specifically for weight management
Rybelsus: An oral semaglutide product approved for type 2 diabetes
Wegovy tablets: An oral semaglutide option approved for eligible adults
The product prescribed should match the patient’s medical needs and available coverage.
What Is Tirzepatide?
Tirzepatide activates two hormone receptors:
GIP: Glucose-dependent insulinotropic polypeptide
GLP-1: Glucagon-like peptide-1
Because tirzepatide acts on both pathways, it is often called a dual GIP/GLP-1 receptor agonist.
Tirzepatide can:
Reduce hunger
Increase fullness
Decrease food intake
Improve glucose regulation
Slow gastric emptying
Produce substantial weight loss
Its brand names include:
Zepbound: FDA-approved for chronic weight management in eligible patients and for moderate-to-severe obstructive sleep apnea in adults with obesity
Mounjaro: FDA-approved for type 2 diabetes
Zepbound and Mounjaro contain the same active ingredient but are approved and marketed for different indications.
Which Produces More Weight Loss?
The most useful comparison comes from SURMOUNT-5, a 72-week randomized trial that directly compared the maximum tolerated doses of tirzepatide and semaglutide in adults with obesity who did not have diabetes. Keep in mind that this research was done by the pharmaceutical company Eli Lilly (the maker of Zepbound/Mounjaro/(tirzepatide))
Average weight loss at 72 weeks was:
20.2% with tirzepatide
13.7% with semaglutide
Average waist-circumference reduction was:
18.4 cm with tirzepatide
13.0 cm with semaglutide
Participants receiving tirzepatide were also more likely to achieve weight-loss thresholds of at least 10%, 15%, 20%, and 25%. Aronne et al., 2025
For a person starting at 250 pounds, the trial averages would represent approximately:
50.5 pounds with tirzepatide
34.3 pounds with semaglutide
These are averages—not promises. Some people lose more, some lose less, and some do not tolerate the doses used in the study.
Does Tirzepatide Work Better for Everyone?
No.
Clinical-trial averages describe groups of participants. They cannot predict exactly how an individual will respond.
A patient may:
Respond exceptionally well to semaglutide
Have fewer side effects with semaglutide
Prefer semaglutide based on prior experience
Have better insurance coverage for one medication
Lose more weight than average with either medication
Have limited weight loss with both medications
Tolerate one but not the other
If semaglutide is producing clinically meaningful weight loss, appetite control, metabolic improvement, and manageable side effects, switching solely because tirzepatide has a higher trial average may not be necessary.
How Are the Doses Increased?
Wegovy Injection
The usual FDA-approved escalation schedule begins with:
0.25 mg weekly for four weeks
0.5 mg weekly for four weeks
1 mg weekly for four weeks
1.7 mg weekly for four weeks
1.7 or 2.4 mg weekly as a maintenance dose, with 2.4 mg recommended when tolerated
Zepbound
The usual escalation begins with:
2.5 mg weekly for four weeks
5 mg weekly
Further increases in 2.5 mg increments after at least four weeks at the current dose when clinically appropriate
Maintenance doses of 5, 10, or 15 mg weekly for weight reduction
Maximum dose of 15 mg weekly
Starting doses are intended for treatment initiation and tolerability. They do not represent the medications’ maximum weight-loss effect.
Dose escalation may need to be delayed when side effects are significant. Faster escalation does not guarantee better long-term results and may make treatment harder to tolerate.
Are the Side Effects Different?
The side-effect profiles are generally similar because both medications activate the GLP-1 receptor.
Common side effects include:
Nausea
Diarrhea
Constipation
Vomiting
Abdominal discomfort
Indigestion
Reflux
Reduced appetite
Injection-site reactions
Fatigue
Gastrointestinal symptoms are often most noticeable during dose escalation and may improve with time.
The direct SURMOUNT-5 comparison did not show a dramatic difference that allows clinicians to predict which medication an individual patient will tolerate better. Gastrointestinal symptoms were the most common adverse events with both medications.
A patient who experiences severe gastrointestinal effects with one medication should not assume the other will be symptom-free.
Important Risks and Contraindications
Both medications carry warnings and precautions related to:
Acute pancreatitis
Gallbladder disease
Dehydration and acute kidney injury
Severe gastrointestinal reactions
Hypoglycemia when used with insulin or certain diabetes medications
Serious hypersensitivity reactions
Potential risk during anesthesia or deep sedation because of delayed gastric emptying
Pregnancy
Suicidal behavior or thinking precautions in the weight-management labels
Both products carry a boxed warning regarding thyroid C-cell tumors observed in rodents. It is unknown whether these medications cause medullary thyroid carcinoma in humans.
They are contraindicated in patients with:
A personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2
A previous serious hypersensitivity reaction to the medication or its ingredients
These medications should not be combined with another product containing the same active ingredient or with another GLP-1 receptor agonist.
Tirzepatide and Oral Birth Control
Tirzepatide may reduce the effectiveness of oral hormonal contraceptives because of its effect on gastric emptying.
The FDA prescribing information advises patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method for:
Four weeks after starting tirzepatide
Four weeks after every dose increase
This interaction is particularly important because fertility may improve with weight loss or improved ovulation.
Semaglutide does not carry the same specific oral-contraceptive instruction, although neither medication should be used for weight loss during pregnancy.
What About Cardiovascular Disease?
Semaglutide has direct cardiovascular-outcomes evidence in adults with overweight or obesity and established cardiovascular disease who did not have diabetes.
In the SELECT trial, semaglutide reduced the risk of major cardiovascular events compared with placebo. Lincoff et al., 2023
Wegovy carries an FDA-approved indication to reduce the risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke in eligible adults with established cardiovascular disease and overweight or obesity.
This may be an important consideration for certain patients.
Tirzepatide has strong effects on weight and cardiometabolic risk factors, but medication selection should be based on the patient’s specific diagnoses and the currently approved indications—not weight-loss percentage alone.
What About Obstructive Sleep Apnea?
Zepbound is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity, together with a reduced-calorie diet and increased physical activity.
Clinical trials found that tirzepatide reduced:
Apnea-hypopnea index
Body weight
Hypoxic burden
Inflammatory measurements
For an eligible patient with obesity and moderate-to-severe obstructive sleep apnea, this indication may influence medication selection. Malhotra et al., 2024
It does not replace individualized sleep-medicine care, and patients should not discontinue CPAP or another prescribed treatment without guidance.
What About Type 2 Diabetes?
Both medications can substantially improve glucose control.
Patients with type 2 diabetes often lose less weight than patients without diabetes, regardless of which medication is used. Insulin use, duration of diabetes, other medications, and individual biology may affect response.
Medication decisions must also account for:
Current A1C
Risk of hypoglycemia
Insulin or sulfonylurea use
Diabetic retinopathy
Kidney disease
Cardiovascular disease
Insurance formularies
Diabetes medications may need adjustment as glucose levels improve.
Which Medication Has Better Appetite Control?
On average, tirzepatide produces greater weight loss, suggesting a stronger overall effect on food intake for many patients. However, appetite response remains individual.
The best medication is not necessarily the one that completely eliminates the desire to eat.
An appropriate response may include:
Less intense hunger
Earlier fullness
Smaller portions
Fewer cravings
Less food noise
Improved control without an inability to eat
Complete appetite suppression can make adequate protein, hydration, and overall nutrition difficult. More suppression is not always better.
Should You Switch if Semaglutide Stops Working?
A switch may be reasonable when:
Semaglutide has been used consistently at an appropriate dose.
Weight loss has been limited.
Hunger remains inadequately controlled.
Significant weight regain is occurring.
Additional weight reduction is clinically indicated.
Tirzepatide is medically appropriate and financially accessible.
Before switching, review:
The actual semaglutide dose
Treatment duration
Missed doses
Product concentration
Injection technique
Side effects
Appetite response
Other medications
Medical conditions
Nutrition, activity, sleep, and stress
Changing medications will not correct an incorrect dose, inconsistent use, or an untreated medical contributor.
Can You Switch Directly From One to the Other?
Yes. In many cases, a patient can transition directly from one GLP-1 medication to another without a washout period. For weekly injections, the new medication is generally started when the next dose would have been due.
Patients who are established on and tolerating a higher dose do not always need to restart treatment at the lowest introductory dose. The prescriber may select an approximate transition dose based on:
The current medication and dose
How long the patient has taken that dose
Treatment response and gastrointestinal tolerance
Whether any doses were missed
Diabetes and other glucose-lowering medications
The reason for switching
Individual medical risks
The table below provides suggested transition doses for patients switching without a significant interruption in treatment. These are clinical conversion guidelines—not exact milligram-for-milligram equivalents or FDA-established conversion doses.
A lower starting dose may be appropriate when the patient has experienced significant side effects, has had a treatment interruption, or is switching because of medication intolerance. Patients should follow the transition instructions provided by their prescriber and should not overlap GLP-1 medications unless specifically instructed.
What About Compounded Semaglutide or Tirzepatide?
Compounded medications are not FDA-approved versions of Wegovy or Zepbound. Formulations and concentrations may differ between pharmacies.
When using a multidose vial, always verify:
The active ingredient
Concentration in mg/mL
Prescribed dose in milligrams
Volume to inject
Corresponding syringe units
Storage instructions
Beyond-use date
Dispensing pharmacy
“Units” alone do not identify a medication dose. Never copy dosing directions from another patient or online source.
Availability of compounded medications is also affected by federal and state law, drug-shortage status, and the circumstances under which compounding is permitted.
Which One Is Less Expensive?
Cost depends on:
Insurance coverage
Prior-authorization criteria
Employer exclusions
Deductible
Manufacturer programs
Pharmacy
Dose and formulation
Whether the medication is prescribed for diabetes, obesity, cardiovascular risk reduction, or obstructive sleep apnea
Whether a legally compounded option is clinically and legally available
The medication with the lower advertised price is not necessarily the medication that will cost a particular patient less.
Coverage should be verified before assuming either medication is affordable long term. Starting a treatment that cannot be sustained may create an avoidable interruption and increase the risk of weight regain.
Which Medication Is Better?
Based on current head-to-head evidence:
Tirzepatide produces greater average weight loss than semaglutide.
But “better” depends on more than the average number on a scale.
Semaglutide may be preferred when:
It is already working well.
It is better tolerated.
Insurance coverage is better.
Its established cardiovascular risk-reduction indication is particularly relevant.
The patient prefers or has access to an oral Wegovy option.
The clinician determines it is the more appropriate treatment.
Tirzepatide may be preferred when:
Greater average weight reduction is clinically important.
Response to semaglutide has been inadequate.
The patient has obesity with moderate-to-severe obstructive sleep apnea.
Appetite control remains inadequate with semaglutide.
It is medically appropriate and accessible.
Neither medication is automatically correct for every patient.
Bottom Line
Semaglutide and tirzepatide are both effective long-term treatments for obesity.
Semaglutide activates the GLP-1 receptor. Tirzepatide activates both GIP and GLP-1 receptors. In the direct SURMOUNT-5 trial, tirzepatide produced approximately 20.2% average weight loss, compared with 13.7% with semaglutide at 72 weeks.
That difference is clinically meaningful, but it does not make tirzepatide universally superior for every patient.
The best choice is the medication that:
Is medically appropriate
Produces meaningful benefit
Has tolerable side effects
Is financially sustainable
Fits the patient’s health conditions and goals
Can be monitored safely over time
Ready to Start Your Weight Management Journey?
GLP-1 medications can be powerful tools, but the right medication, dose, and rate of dose escalation can be different for each person.
At Optima Vida Healthcare, weight management is individualized based on your health history, previous treatments, response to medication, side effects, goals, and long-term needs.
Treatment may include GLP-1 or other weight-management medications when medically appropriate, along with ongoing monitoring and support.
Start Your Weight Management Evaluation →
Or Visit www.ovhmed.com for more information.
Prescription medication is not guaranteed and is prescribed only when clinically appropriate after evaluation by a licensed healthcare provider.
Medical Disclaimer
This information is provided for general educational purposes only and is not a substitute for individualized medical advice, diagnosis, or treatment.
References
Aronne LJ, Sattar N, Horn DB, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393:26–36. https://doi.org/10.1056/NEJMoa2416394
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002. https://doi.org/10.1056/NEJMoa2032183
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–216. https://doi.org/10.1056/NEJMoa2206038
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes. N Engl J Med. 2023;389:2221–2232. https://doi.org/10.1056/NEJMoa2307563
Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193–1205. https://doi.org/10.1056/NEJMoa2404881
U.S. Food and Drug Administration. Wegovy Prescribing Information. Revised 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf
U.S. Food and Drug Administration. Zepbound Prescribing Information. Revised February 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf
This article is provided for general educational purposes and is not a substitute for individualized medical advice, diagnosis, or treatment. Do not start, stop, combine, or change the dose of weight-management medication without guidance from an appropriately licensed healthcare professional.
Contact
Optima Vida Healthcare, LLC
Telehealth medical services
support@ovhmed.com
© 2026 Optima Vida Healthcare, LLC. All rights reserved.